Cargando…
rhIGF-1 Therapy for Growth Failure and IGF-1 Deficiency in Congenital Disorder of Glycosylation Ia (PMM2 Deficiency)
Background. Congenital disorders of glycosylation (CDG) are a group of rare disorders in which glycosylation required for proper protein-protein interactions and protein stability is disrupted, manifesting clinically with multiple system involvement and growth failure. The insulin-like growth factor...
Autores principales: | Miller, Bradley S., Duffy, Meghann M., Addo, O. Yaw, Sarafoglou, Kyriakie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586814/ https://www.ncbi.nlm.nih.gov/pubmed/26425584 http://dx.doi.org/10.1177/2324709613503316 |
Ejemplares similares
-
Assessment of compatibility of rhIGF-1/rhIGFBP-3 with neonatal intravenous medications
por: Salamat-Miller, Nazila, et al.
Publicado: (2022) -
rhIGF-1 Therapy: A Silver Bullet for Bronchopulmonary Dysplasia
Prevention?
por: Plosa, Erin J., et al.
Publicado: (2020) -
Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome
por: Bang, Peter, et al.
Publicado: (2020) -
rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial
por: Ley, David, et al.
Publicado: (2018) -
rhIGF-1/BP3 Preserves Lung Growth and Prevents Pulmonary Hypertension in Experimental Bronchopulmonary Dysplasia
por: Seedorf, Gregory, et al.
Publicado: (2020)